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It is generally recognized that the connecting peptide (C-
peptide) of proinsulin fulﬁlls an important function in the
biosynthesis of insulin. It brings together the A- and B-
chains such that the initial folding and interchain disulﬁde
bonds can be formed. Evolutionary considerations suggest
that a length of approximately 30 residues for the connecting
segment, as is the case for human C-peptide, is optimal
for the eﬃcient further processing of the molecule (i.e., its
cleavage into insulin and C-peptide). Following this, the two
are stored in secretory granules and eventually coreleased
into the circulation. Because of its intimate connection to
theinsulinbiosynthesis,C-peptidehasbeenusedasamarker
of insulin secretion. As such, it has contributed importantly
to our understanding of the pathophysiology of several
metabolic disorders, notably type 1 and type 2 diabetes.
The possibility that C-peptide may possess biological
eﬀects of its own was considered but received relatively little
attention at the time of its discovery in 1968. No detectable
inﬂuence on glucose metabolism or on lipolysis of isolated
fat cells could be observed. In the absence of any insulin-
like eﬀect by C-peptide in isolated cell systems or when
administered to healthy individuals, it was concluded that C-
peptidewaswithoutbiologicaleﬀectotherthanitsroleinthe
biosynthesis of insulin; for a review see [1]. Consequently, C-
peptide as a bioactive peptide left the scientiﬁc limelight and
the interest was focused instead on its usefulness as a marker
of insulin secretion.
It was not until the early 1990s that direct C-peptide
eﬀects were re-evaluated. A series of studies was undertaken
involving administration of the peptide in type 1 diabetes
patients, who lack C-peptide [2]. This proved a useful
approach and it became apparent that replacement of
physiological concentrations of C-peptide in this patient
group results in signiﬁcant amelioration of diabetes-induced
abnormalitiesofregionalbloodﬂowaswellasimprovements
in peripheral nerve and kidney function. These surprising
ﬁndings, subsequently conﬁrmed and extended by several
laboratories, prompted a renewed interest in C-peptide
as a bioactive peptide in its own right. Since then, a
steadily increasing number of reports on new aspects of
C-peptide physiology have been presented. Today, a vast
body of scientiﬁc evidence is available comprising in vitro
studies of the peptide’s membrane interaction and cellular
eﬀects, in vivo studies in animal models of type 1 diabetes
deﬁning C-peptide’s inﬂuence on functional and structural
abnormalities of the kidneys and the peripheral nerves as
wellasclinicaltrialsonnerveandkidneyfunctioninpatients
with type 1 diabetes, all of which attest to a wide spectrum
of physiological eﬀects being mediated by C-peptide. In
addition, the ﬁndings provide a basis for the notion that C-
peptide administration, in combination with regular insulin
therapy,maybebeneﬁcialinthepreventionandtreatmentof
microvascular complications of type 1 diabetes.
In the present, special issue of Experimental Diabetes
Research, most of the recent developments in C-peptide
researcharebeingreviewedincludinganauthoritativereview
of the history and diagnostic aspects of C-peptide. A highly
qualiﬁed attempt is made to sort out the multitude of
intracellular eﬀects of C-peptide, seemingly contradictory
when studied in diﬀerent cell systems and under varying
experimental conditions. Perhaps the most compelling end
eﬀect of C-peptide is its stimulatory inﬂuence on the
microcirculation in a number of tissues, achieved via both
activation and induction of endothelial nitric oxide synthase.
These events are reviewed as are the beneﬁcial eﬀects of C-
peptide and its C-terminal hexa- and pentapeptide segments
onthediabetes-inducedreductionofredbloodcelldeforma-
bility. A possible stimulatory eﬀect by C-peptide on glucose2 Experimental Diabetes Research
uptake is discussed on the basis of both in vitro experiments
and ﬁndings in type 1 diabetes patients. It is, however, noted
that interpretation of such results is confounded by the
recent observation that C-peptide may elicit disaggregation
of insulin hexamers, thereby augmenting the availability of
bioactive insulin monomers [3].
C-peptide and its inﬂuence on renal physiology, partic-
ularly tubular function, are discussed. Likewise, C-peptide
eﬀects on the peripheral and central nervous system are
reviewed. Much new and valuable information in this
central area of C-peptide research has been presented from
Anders Sima’s laboratory. The comprehensive ﬁndings now
point towards a need for clinical trials and the current
situation regarding clinical studies in patients with diabetic
neuropathy is described. Finally, the possibility that C-
peptide may serve as a mediator in the development of
atherosclerotic lesions is discussed. Is the peptide guilty as
charged or wrongly accused? Only future studies can tell but,
attesting to the rapid developments in the ﬁeld of C-peptide
physiology, a study just published reports that physiological
as opposed to elevated concentrations of C-peptide serve
to diminish hyperglycemia-induced vascular smooth muscle
proliferation [4].
The purpose of this issue is to provide an update of
our understanding of C-peptide physiology and the role of
C-peptide deﬁciency in the development of microvascular
complications of type 1 diabetes. Clearly, there is much more
to be learned about C-peptide. Identiﬁcation of a receptor
or the mechanism whereby C-peptide interacts with the cell
membrane has a high priority. On the clinical side, further
trials of long duration are needed to deﬁne the possible role
for C-peptide, together with insulin, in the treatment of
type 1 diabetes. A major obstacle for extended clinical trials
has been the lack of GMP-produced C-peptide suitable for
human use. It is hoped that the evidence summarized in this
issue will convey the urgency with which clinical studies are
needed and stimulate the interest of funding organizations
and the pharmaceutical industry to become involved in this
rapidly developing ﬁeld.
Thomas Forst
John Wahren
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